Pancreatic Cancer Research

ResearcherUniversity of Florida HealthActive in the last 2 years

Andrew R. Judge

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4488-291X; OpenAlex author ID A5060957121; NIH RePORTER profile ID 9223714. Sources: ClinicalTrials.gov.

Their work

Papers
20 (first author 0, last author 7)
Trials
1 (principal investigator on 1)
Grants
2
Labs led
1
Collaborators
48
Papers, trials and grants by year

2016: 1 trial · 2017: 3 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers, 1 grant · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: 5 papers · 2026: 1 paper, 1 grant

Papers 20

  1. Pancreatic Cancer Disrupts Circadian Patterns of Gene Expression in Cardiorespiratory Muscles. Co-author DOI 10.1002/jcsm.70383↗
  2. Local Inflammation Precedes Diaphragm Wasting and Fibrotic Remodelling in a Mouse Model of Pancreatic Cancer. Co-author DOI 10.1002/jcsm.13668↗
  3. Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43856-025-01277-9↗
  4. Role of myofiber-specific FoxP1 in pancreatic cancer-induced muscle wasting. Last author DOI 10.1152/ajpcell.00701.2024↗
  5. The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-25-0237↗
  6. Complement pathway activation mediates pancreatic cancer-induced muscle wasting and pathological remodeling. Last author DOI 10.1172/jci178806↗
  7. Heterogeneity of weight loss and transcriptomic signatures in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jcsm.13390↗
  8. Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of t… Last author DOI 10.3389/fonc.2024.1362244↗
  9. Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery. Last author DOI 10.1002/cam4.4416↗
  10. Depleting Ly6G Positive Myeloid Cells Reduces Pancreatic Cancer-Induced Skeletal Muscle Atrophy. Last author DOI 10.3390/cells11121893↗
  11. Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1002/onco.13853↗
  12. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pan… Co-author DOI 10.3390/cancers13040809↗
  13. Nicotine Induces IL-8 Secretion from Pancreatic Cancer Stroma and Worsens Cancer-Induced Cachexia. Co-author DOI 10.3390/cancers12020329↗
  14. Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor … Co-author DOI 10.1002/cam4.2180↗
  15. IL-8 Released from Human Pancreatic Cancer and Tumor-Associated Stromal Cells Signals through a CXCR2-ERK1/2 Axis to Induce Muscle Atrophy. Last author DOI 10.3390/cancers11121863↗
  16. Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival. Last author DOI 10.1093/jncics/pky043↗
  17. Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine. Co-author DOI 10.3390/ijms19123836↗
  18. A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2016.09.038↗
  19. Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Huma… Co-author DOI 10.1097/mpa.0000000000000843↗
  20. Human pancreatic cancer xenografts recapitulate key aspects of cancer cachexia. Co-author DOI 10.18632/oncotarget.13593↗

Trials 1

  1. The Role of Muscle Cachexia in Pancreatic Cancer Principal investigator NCT02515513↗

Grants 2

  1. The Complement System and Cancer Cachexia R01AR081648↗
  2. FoxO signaling and skeletal muscle atrophy R01AR060209↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sarah M. Judge · 16 shared papers, 2017–2026 · strength 2.54
  2. Jose Gilberto Trevino · 13 shared papers, 2017–2025 · strength 1.62
  3. Carl Atkinson · 1 shared paper, 1 shared grant, 2025–2026 · strength 1.55
  4. Jeremy B. Ducharme · 3 shared papers, 2025–2026 · strength 0.90
  5. Chandler S. Callaway · 4 shared papers, 2019–2025 · strength 0.79
  6. Andrew C. D’Lugos · 4 shared papers, 2019–2025 · strength 0.79
  7. Thomas J. George · 7 shared papers, 2017–2024 · strength 0.74
  8. Daria Neyroud · 3 shared papers, 2022–2025 · strength 0.70
  9. Steven J. Hughes · 7 shared papers, 2017–2024 · strength 0.68
  10. Martin M. Schonk · 2 shared papers, 2025–2026 · strength 0.62
  11. Daniel Delitto · 7 shared papers, 2017–2020 · strength 0.56
  12. Miles E. Cameron · 5 shared papers, 2018–2022 · strength 0.54
  13. Michael R. Deyhle · 3 shared papers, 2019–2025 · strength 0.51
  14. Jennifer B. Permuth · 4 shared papers, 2018–2025 · strength 0.45
  15. Michael H. Gerber · 5 shared papers, 2017–2020 · strength 0.39
  16. Daniel K. Jeong · 3 shared papers, 2019–2025 · strength 0.38
  17. Dung‐Tsa Chen · 3 shared papers, 2019–2025 · strength 0.38
  18. Jason B. Fleming · 3 shared papers, 2019–2025 · strength 0.38
  19. Pamela Joy Hodul · 3 shared papers, 2019–2025 · strength 0.38
  20. Patrick W. Underwood · 3 shared papers, 2018–2022 · strength 0.34
  21. Nathan H. Parker · 2 shared papers, 2025 · strength 0.31
  22. Evan W. Davis · 2 shared papers, 2025 · strength 0.31
  23. José M. Pimiento · 2 shared papers, 2025 · strength 0.31
  24. Vic Velanovich · 2 shared papers, 2025 · strength 0.31
  25. Paul A. Stewart · 2 shared papers, 2025 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.